The immunological efficacy of serogroup B meningococcal protein-polysaccharide vaccine was studied in newly developed immune bacteriolysis test. Serogroup B meningococcus strains had different sensitivities to the bactericidal effects of immune sera. A single injection of the vaccine caused an induction of bactericidal antibodies to meningococcus vaccinal strain. Three weeks after vaccination 77.7% of the vaccines developed an appreciable increase of the titers of bactericidal antibodies to the homologous strain of meningococcus. The concentration of bactericidal antibodies to strain 2394 differing from the homologous strain by its serotype did not increase. In the controls no changes in the titers of bactericidal antibodies to both strains of meningococcus were observed, the level of antibodies being the same as that before vaccination in the group of subjects immunized with B vaccine; this proves the specificity of the immunizing effect to serogroup B meningococcus vaccinal strain (No 125).
Download full-text PDF |
Source |
|---|
Publication Analysis
Top Keywords
Similar Publications
Rational selection of TbpB variants yields a bivalent vaccine with broad coverage against Neisseria gonorrhoeae.
NPJ Vaccines
January 2025
Department of Molecular Genetics, Temerty Faculty of Medicine, University of Toronto, Toronto, Canada.
Neisseria gonorrhoeae is an on-going public health problem due in part to the lack of success with efforts to develop an efficacious vaccine to prevent this sexually transmitted infection. The gonococcal transferrin binding protein B (TbpB) is an attractive candidate vaccine antigen. However, it exhibits high levels of antigenic variability, posing a significant obstacle in evoking a broadly protective immune response.
View Article and Find Full Text PDFSerum bactericidal activity against meningococcus in patients with systemic lupus erythematosus.
Clin Exp Pediatr
January 2025
Department of Pediatrics, Hallym University Sacred Heart Hospital, Anyang, Korea.
Background: Patients with systemic lupus erythematosus (SLE) are susceptible to infectious diseases owing to various immunosuppressive treatments and disease characteristics. Meningococcal infections progress rapidly with a high incidence of severe complications and mortality; therefore, meningococcal vaccination is needed. However, there is limited evidence regarding the immunity and immunogenicity of patients with SLE.
View Article and Find Full Text PDFEfficacy of hyperimmunized egg yolk antibodies (IgY) against Campylobacter jejuni: In Vitro and In Vivo evaluations.
Poult Sci
January 2025
Prestage Department of Poultry Science, College of Agriculture and Life Sciences, North Carolina State University, Raleigh, NC 27695-7608. Electronic address:
Campylobacter infections are a prevalent cause of diarrheal disease in humans and are the most significant zoonotic pathogens worldwide. Human campylobacteriosis is generally via ingestion of contaminated poultry products. However, based on recent studies chicken egg yolk antibody (IgY) powder has great potential to reduce the cecum load of Campylobacter jejuni (C.
View Article and Find Full Text PDFTransgenic as a Promising Oral Vaccine Carrier: Potential Application in the Aquaculture Industry.
Mar Drugs
December 2024
State Key Laboratory of Bioreactor Engineering, East China University of Science and Technology, Shanghai 200237, China.
SR21, a kind of eukaryotic heterotrophic organism rich in unsaturated fatty acids, is an emerging microbial alternative to fish oil. The dietary inclusion of 15% SR21 was optimal for the growth performance of zebrafish. Previous studies demonstrated that fructose-1,6-bisphosphate aldolase (FBA) of is a valuable broad-spectrum antigen against various pathogens in aquaculture (e.
View Article and Find Full Text PDFBackground: A MenABCWY vaccine containing 4CMenB and MenACWY-CRM vaccine components has been developed to protect against the five meningococcal serogroups that cause most invasive disease cases.
Methods: In this phase 3 study (NCT04707391), healthy participants aged 15-25 years, who had received MenACWY vaccination ≥4 years previously, were randomized (1:1) to receive two MenABCWY doses six months apart or one MenACWY-CRM dose. Primary objectives were to demonstrate the non-inferiority of MenABCWY 1 month post-vaccination versus MenACWY-CRM, with a lower limit of 2-sided 95% confidence interval above -10% for group differences in 4-fold rise in human serum bactericidal antibody (hSBA) titers against serogroups ACWY, and to evaluate reactogenicity and safety.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!